Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT576 in relapsed/refractory multiple myeloma
NCT05182073Phase 1Completed
- Sponsor
- Fate Therapeutics
- Start
- Nov 2021
- Primary completion
- Sep 2024
- Modality
- CAR-T Cells, Patient-derived iPSCs, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT576 in multiple myeloma (MM) (4 arms), sponsored by Fate Therapeutics. Primary endpoints: Dose-Limiting Toxicities, Recommended Phase 2 Dose and 1 more. Started Nov 2021; status: completed.
02
Drugs
FT576
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05182073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182073.